Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mast cell depletion and repopulation dynamics define briquilimab efficacy in a mouse model of allergic asthma.

The Journal of allergy and clinical immunology·2026

Same author

Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human-Mouse KIT.

Allergy·2025

Same author

Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates.

The Journal of allergy and clinical immunology·2025

Same author

Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial.

Nature medicine·2025

Same author

REMOVED: Allogeneic Hematopoietic Cell Transplantation with Briquilimab (JSP191) Anti-CD117 Antibody-Based Nonmyeloablative Conditioning for GATA2 Deficiency.

Transplantation and cellular therapy·2025

Same author

Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia.

Transplantation and cellular therapy·2024

Search research articles

Related Experiment Video

Updated: May 23, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Anemia in the elderly.

Wendy W Pang¹, Stanley L Schrier

¹Department of Medicine, Stanford University, Stanford, California 94305, USA.

Current Opinion in Hematology

|April 13, 2012

Summary

This summary is machine-generated.

Large-scale studies and comprehensive evaluations reveal distinct causes of anemia in the elderly. Unexplained anemia remains prevalent, while iron deficiency often stems from blood loss in Western populations.

More Related Videos

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

Related Experiment Videos

Last Updated: May 23, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

Area of Science:

Geriatric Medicine
Hematology
Epidemiology

Background:

Anemia is a significant health concern in the elderly population.
Previous large-scale studies like NHANES III provided prevalence data but relied on screening evaluations.
Recent studies offer comprehensive hematologic evaluations for elderly outpatients.

Purpose of the Study:

To compare findings from large-scale screening studies with comprehensive hematologic evaluations of anemia in the elderly.
To analyze the causes and prevalence of different types of anemia in older adults.

Main Methods:

Review and comparison of data from large-scale epidemiologic surveys (e.g., NHANES III).
Analysis of findings from smaller, comprehensive hematologic evaluations with therapeutic interventions and follow-up.
Examination of patient cohorts from hematology clinics.

Main Results:

Unexplained anemia is a persistent finding, accounting for 30-46% of cases even with comprehensive evaluation.
Iron-deficiency anemia in North America and Western Europe is frequently linked to blood loss, necessitating further investigation.
Myelodysplastic syndromes represent a significant cause of anemia in the elderly, with a prevalence of at least 4%.

Conclusions:

Large-scale screening studies are crucial for understanding anemia prevalence in the elderly.
Comprehensive hematologic evaluations are essential to complement screening data for a more accurate clinical picture.
Identifying the specific causes of anemia, such as blood loss or myelodysplastic syndromes, is critical for effective management in older adults.